Abstract
The field of replication-selective oncolytic viruses (virotherapy) has exploded over the last 10 years. As with many novel therapeutic approaches, initial overexuberance has been tempered by clinical trial results with first-generation agents. Although a number of significant hurdles to this approach have now been identified, novel solutions have been proposed and improvements are being made at a furious rate. This article seeks to initiate a discussion of these hurdles, approaches to overcome them, and unique safety and regulatory issues to consider.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Southam CM . Present status of oncolytic virus studies Ann NY Acad Sci 1960 656–673
Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM . Experimental therapy of human glioma by means of a genetically engineered virus mutant Science 1991 252: 854–856
Lorence RM, Rood PA, Kelley KW . Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity J Natl Cancer Inst 1988 80: 1305–1312
Coffey M, Strong J, Forsyth P, Lee P . Reovirus therapy of tumors with activated ras pathway Science 1998 282: 1332–1334
Stojdl DF et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus Nat Med 2000 6: 821–825
Rommelaere J, Cornelis JJ . Antineoplastic activity of parvoviruses J Virol Methods 1991 33: 233–251
Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM . Experimental therapy of human glioma by means of a genetically engineered virus mutant Science 1991 252: 854–856
Bischoff JR et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [see comments] Science 1996 274: 373–376
Heise C et al. ONYX-015, an E1B gene–attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents [see comments] Nat Med 1997 3: 639–645
Mastrangelo M, Eisenlohr L, Gomella L, Lattime E . Poxvirus vectors: orphaned and underappreciated J Clin Invest 2000 105: 1031–1034
Heise C et al. An adenovirus E1A mutant that demonstrates potent and selective antitumoral efficacy Nat Med 2000 6: 1134–1139
Fueyo J et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo Oncogene 2000 19: 2–12
Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH, Wimmer E . Intergeneric poliovirus recombinants for the treatment of malignant glioma [see comments] Proc Natl Acad Sci USA 2000 97: 6803–6808
Miyatake S, Iyer A, Martuza RL, Rabkin SD . Transcriptional targeting of herpes simplex virus for cell-specific replication J Virol 1997 71: 5124–5132
Wickham TJ, Shears TEL, Roelvink P et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins J Virol 1997 71: 8221–8229
Alemany R, Curiel DT . The development of replicative adenoviruses for cancer therapy Clin Cancer Res 2000 6: 3395–3399
Heise C, Williams A, Olesch J, Kirn D . Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects Cancer Gene Ther 1999 6: 499–504
Ganly I et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 2000 6: 798–806
Wu JT, Byrne HM, Kirn DH, Wein LM . Modeling and analysis of a virus that replicates selectively in tumor cells Bull Math Biol 2001 63: 731–768
Chinnadurai G . Adenovirus 2 Ip+ locus codes for a 19 kD tumor antigen that plays an essential role in cell transformation Cell 1983 33: 759–766
Sauthoff H, Heitner S, Rom W, Hay J . Deletion of the adenoviral E1B–19 kD gene enhances tumor cell killing of a replicating adenoviral vector Hum Gene Ther 2000 11: 379–388
Doronin K et al. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein J Virol 2000 74: 6147–6155
Shenk T . In: Fields K, Howley P, eds Fields Virology Philadelphia: Lippincott-Raven 1996 2135–2137
Smith GL, Vanderplasschen A . Extracellular enveloped vaccinia virus. Entry, egress, and evasion Adv Exp Med Biol 1998 440: 395–414
Douglas J, Kim M, Sumerel L, Carey D, Curiel D . Efficient oncolysis by a replicating adenovirus in vivo is critically dependent on tumor expression of primary Ad receptors Cancer Res 2001 61: 813–817
Rauen KA et al. Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy Cancer Res 2002 62: 3812–3818
Vasey P, Shulman L, Gore M, Kirn D, Kaye S . Phase I trial of intraperitoneal Onyx-015 adenovirus in patients with recurrent ovarian carcinoma Proc Am Soc Clin Oncol 2000 19: 1512 (Abstract)
Nemunaitis J et al. Selective replication and oncolysis in p53 mutant tumors with Onyx-015, an E1B–55 kD gene–deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial Cancer Res 2000 60: 6359–6366
Mulvihill S, Warren R, Kirn D . Safety and feasibility of injection with an E1B–55 kD gene–deleted replication-selective adenovirus Onyx-015 into primary carcinomas of the pancreas: a phase I trial Gene Ther 2001 8: 308–315
Roelvink P, Mi G, Einfeld D, Kovesdi I, Wickham T . Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae Science 1999 286: 1568–1571
Suzuki K et al. A replicative adenovirus with enhanced infectivity shows improved oncolytic potency Clin Cancer Res 2001 7: 120–126
Kirn D . Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther 2001 8: 89–98
Toda T et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus Hum Gene Ther 1999 10: 2741–2755
Herrlinger U et al. Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector Gene Ther 1998 5: 809–819
Merritt J et al. Clinical phase I experience with INGN 201 (Ad-p53) in non-small cell lung cancer and head and neck cancer Cancer Gene Ther 1997 4: S12 (Abstract)
Reid T et al. Hepatic artery infusion of Onyx-015, a replication-selective adenovirus, in combination with 5-FU/leucovorin for gastrointestinal carcinoma metastatic to the liver: a phase I/II clinical trial Proc Am Soc Clin Oncol 2000 19: 953 (Abstract)
Reid T et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial Gene Ther 2001 8: 1618–1626
Nemunaitis J et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity Gene Ther 2001 8: 746–759
Pecora AL et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers J Clin Oncol 2002 20: 2251–2266
Kirn D . Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer Oncogene 2000 1: 6660–6668
Vanderplasschen A, Mathew E, Hollinshead M, Sim RB, Smith GL . Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope Proc Natl Acad Sci USA 1998 95: 7544–7549
Heise C, Williams A, Xue S, Propst M, Kirn D . Intravenous administration of ONYX-015, a selectively-replicating adenovirus, induces antitumoral efficacy Cancer Res 1999 59: 2623–2628
Ikeda K, Chiocca N . Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited anti-viral responses Nat Med 1999 5: 881–887
Gnant MF, Puhlmann M, Alexander HR Jr, Bartlett DL . Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice Cancer Res 1999 59: 3396–3403
Gnant MF et al. Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases J Natl Cancer Inst 1999 91: 1744–1750
Kirn D, Warren R . Liver-directed therapy with p53-targeted adenoviruses: clinical trial results Surg Clin North Am 2002 (In press)
Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL . Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas Nat Med 1995 1: 938–943
Markert J et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial Gene Ther 2000 7: 867–874
Hermiston T . Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer J Clin Invest 2000 105: 1169–1172
Toda M, Martuza RL, Kojima H, Rabkin SD . In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity J Immunol 1998 160: 4457–4464
Wildner O, Blaese RM, Morris JM . Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase Cancer Res 1999 59: 410–413
Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH . A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy [see comments] Hum Gene Ther 1998 9: 1323–1333
Kurihara T, Brough DE, Kovesdi I, Kufe DW . Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen J Clin Invest 2000 106: 763–771
Russell SJ . Gene therapy for cancer Lancet 1992 339: 1109–1110
Haag A et al. Highly efficient transduction and expression of cytokine genes in human tumor cells by means of autonomous parvovirus vectors; generation of antitumor responses in recipient mice Hum Gene Ther 2000 11: 597–609
McCart JA et al. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression Gene Ther 2000 7: 1217–1223
Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity Proc Natl Acad Sci USA 1993 90: 3539–3543
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vile, R., Ando, D. & Kirn, D. The oncolytic virotherapy treatment platform for cancer: Unique biological and biosafety points to consider. Cancer Gene Ther 9, 1062–1067 (2002). https://doi.org/10.1038/sj.cgt.7700548
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700548
Keywords
This article is cited by
-
M51R and Delta-M51 matrix protein of the vesicular stomatitis virus induce apoptosis in colorectal cancer cells
Molecular Biology Reports (2019)
-
Prospects for combined use of oncolytic viruses and CAR T-cells
Journal for ImmunoTherapy of Cancer (2017)
-
Development of an HSV-1 neutralization test with a glycoprotein D specific antibody for measurement of neutralizing antibody titer in human sera
Virology Journal (2016)
-
The targeted inhibitory effects of human amniotic fluid stem cells carrying CXCR4 promoter and DAL-1 on non-small cell lung carcinoma growth
Gene Therapy (2016)
-
Oncolytic Virus Immunotherapy for Melanoma
Current Treatment Options in Oncology (2015)